Somewhere in Singapore right now, a woman is sitting in a waiting room holding a printout covered in acronyms. FSH. LH. AMH. E2. Each one has a number beside it. Each number has a small reference range in brackets. And she is quietly trying to work out which of these numbers is the one that decides whether she gets to be a mother.
Here is the part nobody explains at the counter. Not one of those numbers answers that question. They were never built to. A round of fertility screening in Singapore will tell you a great deal about your starting position and almost nothing about your destiny, and confusing the two is the most common mistake made in that waiting room.
The day you book matters
Blood is blood, you would think. It is not. Several hormones on a standard fertility panel swing wildly across a menstrual cycle, and two of the most quoted ones, FSH and estradiol, are only meaningful when drawn in the first few days of it. Day two or day three, usually.
Book your panel on a convenient Thursday in the middle of your cycle and you will still get numbers. They will still have tidy reference ranges beside them. They will simply be describing a different moment in a process that never sits still. It is a bit like judging a tide from one photograph taken at random.
AMH is the exception, which is partly why clinics love it. It stays fairly steady whatever day you walk in. Which brings us to the number almost everyone misreads.
What AMH does not measure
Anti-Mullerian hormone has become the headline act of fertility testing. It is easy to draw, easy to chart, and dangerously easy to turn into a story about how much time you have left. Low AMH, the story goes, means the clock is nearly out.
What AMH actually reflects is roughly how many eggs are sitting in the queue. Not their quality. Not whether this particular month will work. The American Society for Reproductive Medicine has been unusually blunt on this point, cautioning that AMH should not be used on its own to counsel a woman about her chances of conceiving naturally.
Where it genuinely earns its keep is in planning. If treatment is on the table, AMH helps predict how your ovaries will respond to stimulation, which shapes the dose and the expectations. That is useful. It is simply not a countdown.
The test that gets booked last
Meanwhile, across the waiting room, someone’s husband is reading a magazine. He has not been tested. In a surprising number of couples he will not be tested for months, by which point his partner has been through hormone panels, a pelvic ultrasound and possibly a procedure involving a camera.
This is strange, because a semen analysis is the cheapest, fastest and least invasive test in the whole workup. Nothing is injected. Nothing is imaged. A sample is produced, a technician counts and measures, and within days you know whether count, movement and shape sit in normal territory. Male factors contribute to a large share of couples’ difficulties, and every major fertility body recommends testing both partners from the start.
The reason it slips to the back of the queue is not medical. It is social. Ask anyone who works in a fertility clinic and you will hear the same thing: the appointment gets made, then quietly rescheduled.
When screening is worth doing
There is a rule of thumb worth knowing before you spend a year wondering about it.
- Under 35 and trying: give it twelve months of regular unprotected sex before asking for a workup
- Aged 35 or over: make that six months, because the cost of waiting rises
- Irregular or absent periods, known endometriosis, previous pelvic surgery, or two or more miscarriages: go earlier, whatever your age
- Not trying yet, but planning around a career, a move or a partner’s timeline: screening is reasonable purely as information
That last one is newer and badly underrated. Plenty of people screen not because something is wrong, but because they are deciding when to start and would rather decide with data than with guesswork.
A clean result is not a promise
Here is the trade-off that never makes it onto a brochure. A full panel can come back perfectly normal and you can still struggle to conceive. Unexplained infertility is a genuine diagnosis, and it is not rare.
That sounds like an argument against testing. It is the opposite. Normal results cross off a long list of treatable things: a thyroid problem, a structural issue inside the uterus, an ovulation that is not actually happening. Every item eliminated is a month you do not spend chasing the wrong theory.
Screening is not a fortune teller. It is a process of elimination, and elimination is how you reach an answer faster.
So if you are the one holding the printout, the useful question is not which number decides your future. It is which numbers were drawn on the right day, which parts of the picture are still missing, and who else in the room still needs testing. That is a far less dramatic question. It is also the one that actually moves you forward.
